Here is what the page “Personalized mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%” contains. A personalized mRNA cancer vaccine developed by Moderna and Merck reduced the risk of disease recurrence by 42% compared to standard treatment in patients with melanoma, according to new data. The vaccine, known as mRNA-4157 (V940), is tailored to each patient's tumor mutations and is used in combination with Merck's immunotherapy Keytruda. This result comes from a Phase 2b trial involving 157 patients with high-risk melanoma, a form of skin cancer.
The 42% reduction in recurrence or death is a significant improvement over Keytruda alone, which is already a standard of care. The findings, reported by STAT, highlight the potential of personalized cancer vaccines to improve outcomes in difficult-to-treat cancers. Moderna and Merck plan to discuss the data with regulators and have already started a Phase 3 trial. The full version stays on the original page, which this listing opens directly.